Following encouraging interim data from the Phase II REDUC trial of Vacc- 4x with romidepsin, Bionor has set a number of initiatives in motion to fully capitalise on the potential opportunity that this ‘Kick and Kill’ approach could offer in HIV. This includes planning next development steps by convening an expert panel, securing future romidepsin supply and exploring potential financing options. These endeavours should ensure that Bionor will be well-placed to swiftly advance Vacc-4x, if further REDUC data expected in H215 are positive. Our valuation is NOK1bn.
